Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
124
days
Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model
AuthorsChristina Harlev; Elisabeth Krogsgaard Petersen; Mats Bue; Lone Kjeld Petersen; Johanne Gade Lilleøre; Anne Vibeke Schmedes; Bo Martin Bibby; Maiken Stilling
Affiliations1. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 2. Aarhus Denmark Microdialysis Research (ADMIRE), Orthopaedic Research Laboratory, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark; 4. Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 6. Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern, Vejle, Denmark; 7. Department of Biostatistics, Aarhus University, Aarhus, Denmark
42
days
Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy
AuthorsMatthieu Gracia; Sabrina Marsili; Julien Vintejoux; Laurence Gladieff; Etienne Chatelut; Fabienne Thomas
Affiliations1. Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France; 2. Univ Toulouse, Oncopole Claudius-Regaud, IUCT-Oncopole, Toulouse, France
103
days
Lack of effects of S -equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer
AuthorsTakehiko Sambe; Chiyo K. Imamura; Noriko Hida; Taigi Yamazaki; Takuya Mizukami; Kakei Ryu; Koya Fukunaga; Taisei Mushiroda; Haruna Miyakawa; Shigeto Uchiyama; Naoki Uchida; Shinichi Kobayashi
Affiliations1. Division of Clinical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan; 2. Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan; 3. Advanced Cancer Translational Research Institute, Showa Medical University, Tokyo, Japan; 4. Division of Clinical Research and Development, Department of Clinical Pharmacy, Showa Medical University School of Pharmacy, Tokyo, Japan; 5. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; 6. Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd., Saga, Japan
120
days
Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)
AuthorsLin Fang; Xin Jiang; Kexiu Song; Ping Shi; Li Wang; Lingmei Xu; Xianghui Duan; Fei Liu; Feifei Sun; Rongxin Ban; Yaping Ma; Chenjing Wang; Yu Cao
Affiliations1. Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China; 2. Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China; 3. Clinical Medicine Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 4. Clinical Pharmacology Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China; 5. Biostatistics Department, XuanZhu Biopharm Co., Ltd, Shijiazhuang, China
48
days
Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
AuthorsGabriel A. Brooks; Dylan B. Ness; Kathryn C. Hourdequin; Gregory H. Ripple; Manik Amin; Sierra Lord-Halvorson; Wahab A. Khan; Sophie J. Deharvengt; Vincent Busque; Konstantin H. Dragnev; Wenyan Zhao; Tor D. Tosteson; Lionel D. Lewis
Affiliations1. Dartmouth Cancer Center, Lebanon, USA; 2. Geisel School of Medicine, Lebanon, USA; 3. Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, USA; 4. University of Chicago Comprehensive Cancer Center, Chicago, USA
88
days
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity
AuthorsElizabeth Cui; Samantha Medwid; Ute I. Schwarz; Richard B. Kim
Affiliations1. Department of Physiology and Pharmacology, Western University, London, Canada; 2. Department of Medicine, Western University, London, Canada; 3. London Health Sciences Centre Research Institute, London, Canada
102
days
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
AuthorsClaire Brillac; Dorothée Sémiond; Corina Oprea; André Baruchel; C. Michel Zwaan; Laurent Nguyen
Affiliations1. Sanofi Research and Development, Vitry-sur-Seine, France; 2. Sanofi, Cambridge, MA, USA; 3. Robert Debré University Hospital (APHP and Université Paris Cité), Paris, France; 4. Princess Máxima Centre for Pediatric Oncology, Utrecht, The Netherlands, and Department of Pediatric Oncology, Erasmus MC - Sophia Children’s Hospital, Rotterdam, The Netherlands
107
days
Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
AuthorsLina Eltaib; Muhammad Afzal; Chandana Maji; H. Malathi; Kavita Goyal; Haider Ali; Gaurav Gupta; Md Sadique Hussain
Affiliations1. Department of Pharmaceutics, College of Pharmacy, Northern Border University, Rafha, Saudi Arabia; 2. Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia; 3. Noida Institute of Engineering and Technology (Pharmacy Institute), Greater, India; 4. Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, India; 5. Department of Biotechnology, Graphic Era (Deemed to be University), Clement Town, Dehradun, India; 6. Centre for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College, Saveetha University, Chennai, India; 7. Centre for Research Impact & Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura, India; 8. Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, UAE; 9. Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India; 10. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
132
days
Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
AuthorsMartina Catalano; Gestiana Cekrezi; Irene De Gennaro Aquino; Delia Ravizza; Alexandra Paulet; Kristian Shtembari; Claudia De Angelis; Roberto Petrioli; Daniele Generali; Giandomenico Roviello
Affiliations1. Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy; 2. School of Medicine and Surgery, University of Florence, Florence, Italy; 3. Clinical Oncology, Careggi University Hospital, Florence, Italy; 4. Medical Oncology Unit, Careggi University Hospital, Florence, Italy; 5. Unit of Medical Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 6. Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy; 7. Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy
152
days
6-gingerol alleviates chemotherapy-induced nausea and vomiting by inhibiting ferroptosis via the regulation of iron homeostasis
AuthorsWan Liang; Lei Feng; Siyu Han; Chenglu Yang; Binbin Ye; Ziyao Mo; Ke Nie
Affiliations1. School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, P.R. China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days